News

Review a rundown of our top articles and resources for patients inspired by National Eczema Awareness Month.

A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.

Keep up with the latest headlines in dermatology from the past week, including a new immuno-dermatology partnership, promising study results from a combined mRNA vaccine and Keytruda for advanced melanoma, and more.

Here is a recap of the drugs and treatments approved to keep in mind for the new year.

ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.

Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.

The confirmatory phase 3 trial demonstrated significant efficacy of TO-208 versus a placebo.

A poster from the RAD Virtual Conference reviewed the relationship between Black and DHH patients and the shared disparities these populations face.

Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.

Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.

The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.

David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.

Cognizance and certain clues may help dermatologists in recognizing antifungal-resistant dermatophyte infections.

Biolojic’s BD9 is a dual specific antibody that can block both Thymic stromal lymphopoietin and IL-13.

Staying on top of products and ingredients patients are asking about is critical, especially this holiday season as they are considering gifts for loved ones.

52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.

Lesional stability is a necessary requirement for determining the course of treatment for vitiligo.

Study authors hypothesize that a monoclonal blockade of pathogenic T cells may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis.

The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.

One of the specific areas of focus will be non-melanoma skin cancer.

Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

In January 2023, adalimumab-atto became the first biosimilar product available for the reference product adalimumab.

This week’s collection of the latest dermatologic studies covers skin cancer risk associated with phototherapy excluding psoralens, the role of the mycobiome in the development of atopic diseases, underrecognized pediatric vulvar diseases, and sunscreen deserts in Northeast, Ohio.

This article is authored by Dr. Baldo Scassellati Sforzolini, M.D., Ph.D., MBA, Global Head of R&D, Galderma and Dr. Christophe Piketty, M.D., Ph.D., Global Senior Program Head at Galderma. IL-31 is a neuroimmune cytokine that drives the most burdensome symptom in prurigo nodularis and atopic dermatitis, namely itch, and is also involved in skin inflammation and keratinocyte abnormalities.

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.